Introduction: Systemic lupus erythematosus is an autoimmune disease characterized by the production of antinuclear and cytoplasmic antibodies that can affect many organs. Cardiovascular diseases occurring in patients with SLE include myocardial infarction, coronary heart disease, stroke, transient cerebral ischemia, or thromboembolic disorders.
Introduction
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by the production of antinuclear and cytoplasmic antibodies that can affect many organs. SLE presents with a wide spectrum of clinical symptoms. The symptoms may manifest from the cardiovascular and respiratory systems, among other systems, and as hematologic and dermatologic disorders. However, SLE is a disease of a still unknown etiology [1] . SLE occurs worldwide, and the incidence varies depending on the geographic location. The highest and lowest incidence rates have been reported in North America and Africa, respectively. On the other hand, European countries are among the nations with a lower incidence of SLE. The disease more often affects women than men, and the peak of incidence in women occurs between the third and seventh decade of life. In the case of men, the peak of incidence occurs in the fifth to the seventh decade of life [2] . There has been an increase in the survival rate of patients with SLE [3] . The diagnosis of SLE is based on meeting at least 4 of the classification criteria established by the American College of Rheumatology [4] .
Patients with SLE have an increased risk of developing cardiovascular diseases, which are among the most common causes of death in this patient population [5, 6] . Cardiovascular diseases occurring in patients with SLE include myocardial infarction, coronary heart disease, stroke, transient cerebral ischemia, or thromboembolic disorders. The risk factors that contribute to the development of the above diseases include components of the metabolic syndrome (obesity, dyslipidemia, hypertension, and insulin resistance) and smoking. Immunologic factors increasing the risk of cardiovascular complications in SLE have also been identified, such as the presence of antiphospholipid antibodies, proinflammatory cytokines, and factors related to the disease (e.g., glucocorticosteroid therapy, antimalarial drugs, immunosuppressive drugs, and kidney diseases) [7, 8] . Therefore, it is important to identify patients with an increased risk of developing cardiovascular disease. Transthoracic echocardiography (TTE) is used as a noninvasive screening examination for detecting structural and functional disorders of the myocardium in asymptomatic patients with lupus [9] . Assessment of generalized and segmental contractility is important in estimating myocardial efficiency according to left ventricular ejection fraction (LVEF). Such an assessment enables the measurement of myocardial parameters and comparing the results with follow-up measurements, allowing for the accurate observation of patients [10] [11] [12] .
Early identification of heart dysfunction in SLE is important in determining the course of the disease [13] .
Material and methods
The subjects of this study were patients with SLE. The study was conducted in the cardiology clinic of the Silesian Medical University in Katowice. The study results from October 2014 to February 2019 were analyzed, and the study is still ongoing. Informed consent was obtained from patients for inclusion in this study. The study protocol was approved by the local bioethical committee. The analysis included 45 patients with SLE, comprising 40 women aged 55.67 ± 11.34 years and 5 men aged 62.6 ± 8.43 years. The research group was selected in terms of sex and age. The control group consisted of 39 people, including 34 women aged 49.5 ± 12.02 years and 5 men aged 51.8 ± 4.31 years, who did not have serious cardiovascular diseases, especially those of atherosclerotic origin. All patients from this group voluntarily decided to take part in the presented study. Subjects diagnosed with autoimmune diseases, pregnancy and metabolic disorder were excluded from the study. Furthermore, the medical history was obtained retrospectively from the medical records. In this group the diabetes mellitus type 2 occurred in 5.13% of patients and the arterial hypertension occurred in 25.64%. The chronic diseases which had been diagnosed previously were: spine or lower limbs osteoarthritis (12.82%). None of patients from the control group had cancer or was treated with glucocoricosteroids before. SLE was diagnosed using the American College of Rheumatology (ACR) criteria. Afterwards activity of the disease among patients was assessed using Systemic Lupus Erythematosus Disease Activity Index (SLEDAI-2K). Scores of above 6 were a threshold to recognize active disease. The measurements were carried out by qualified personnel under the same conditions. All examinations were conducted in the clinic as part of a planned visit to a specialist. The study group consisted of patients with an SLE diagnosis and an average disease duration of 12.58 ± 8.18 years.
Glucocorticosteroid treatment (prednisone dose ≤7.5 mg/day) was used in 42.22% of patients, antimalarial drugs in standard doses in 37.78%. 6.67% of patients were treated with combination of glucocorticosteroids and antimalarial drugs. Biologic in standard doses was used in 8,89% of patients and azathioprine in standard doses in 8.89%. The exclusion criteria were the presence of an overlap syndrome and organ failure.
Echocardiographic examination was performed with the patient lying on the left side. The LVEF was estimated using the Simpson's biplane method based on echocardiographic imaging from apical two-and four-chamber views. Each record included at least three cardiac cycles. The results of the three measurements were averaged and given as a percentage. The study was performed with a GE Healthcare Vivid 7 ultrasound machine equipped with a 3.6-MHz probe. All tests were performed by one qualified doctor (a cardiology specialist).
The 6MWT was performed according to a standard protocol, administered by a qualified nurse. The test was carried out in a ward corridor specially prepared for testing. The patients walked on a flat surface without obstacles, with markers placed on the wall with the amount of distance shown in meters. Each patient was informed about the purpose of the examination and the method of implementation. Before and after the study, blood saturation, arterial blood pressure, heart rate, and subjective parameters were measured for assessing dyspnea and fatigue according to the Borg scale. The patients performed the test by walking as far as possible within 6 min.
Blood samples for laboratory tests were obtained from each patient on an empty stomach in the morning. Morphologic blood tests were performed, and parameters such as erythrocytes (RBC), leukocytes (WBC), hematocrit, hemoglobin, mean corpuscular volume (MCV), mean corpuscular hemoglobin concentration (MCHC), mean corpuscular hemoglobin (MCH), platelets, mean platelet volume (MPV) and C-reactive protein (CRP) were measured. The plateletto-lymphocyte ratio (PLR) was calculated as the platelet count divided by the lymphocyte count.
Statistical analysis
Microsoft Excel 2016 and Statistica version 13.3 (StatSoft Inc. 2014) were used to analyze the data. Student's t-test was used to analyze variables with normal distribution, and the Mann-Whitney U-test was used for nonparametric values. To calculate the correlation between nonparametric variables, the Spearman method was used. The Pearson correlation test was used for parametric values. Variables are presented as average ± standard deviation or median, and categorical data are summarized as number (percentage). The level of statistical significance was set at p < 0.05. Table 1 shows the anthropometric characteristics of patients with SLE and the control (non-SLE) group. The average age was 56.57 ± 11.25 years for the SLE group and 50.54 ± 11.97 years for the non-SLE group. The average duration of illness of patients with SLE was 12.58 ± 8.18 years. The height was comparable between groups (165.15 ± 7.37 cm in the SLE group and 164.18 ± 5.81 cm in the non-SLE group, p = 0.7818). Patients with SLE had lower average body weight than the control group (72.59 ± 15.32 vs. 73.57 ± 12.20 kg, p = 0.5150). Body mass index was lower in the SLE group (26.71 ± 4.29 vs. 27.61 ± 4.95 kg/m2, p = 0.4627).
Results
In this study, diabetes mellitus type 2 occurred in 8.89% of the SLE group and in 5.13% of the non-SLE group (p = 0.5103). Significantly higher occurrence of hypertension was observed in the SLE group than in the non-SLE group (46.67% vs. 25.64%, p = 0.0471). 0.2575). The median Borg dyspnea index was 2 in the SLE group and 0.5 in the non-SLE group, and the difference was statistically significant (p = 0.0036). The median Borg fatigue index was significantly higher in the SLE group (12) than in the non-SLE group (3) (p = 0.0001). Figure 1 presents the 6MWT results of the study and control groups. In the echocardiographic study, the left ventricular end-diastolic diameter (LVEDD) in the parasternal long-axis view was significantly larger in the SLE group than in the non-SLE group (45.60 ± 6.72 vs. 40.75 ± 6.83 mm, p = 0.0247). Figure 2 . In the study group, 2.22% of patients with SLE showed left ventricular systolic dysfunction. LVEF <30% was present in 2.22% of the patients in the SLE group. LVEF 31%-40% was significantly more often observed in patients with SLE (20% vs. 0%, p = 0.0027).
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LVEF 41%-50% was present in 31.11% of patients with SLE (p = 0.0001). LVEF 51%-60% was significantly more often observed in the non-SLE group than in the SLE group (94.87% vs. 44.55% p = 0.0001). LVEF >60% was present in 2.22% of the SLE group and in 5.13% of the non-SLE group (p = 0.8851). Table 3 shows the LVEF of patients with SLE. A significant correlation was found between the distance covered in 6MWT and the LVEF (r = 0.6585, p = 0.00001).
The disease duration was important in left ventricular systolic dysfunction (r = 0.4516, p = 0.0001) and in the distance covered in 6MWT (r = -0.2201, p = 0.0001). Significant correlations between disease duration and blood counts were found. Disease duration also correlated with HCT (r = 0.4034, p = 0.0376), hemoglobin (r = 0.4280, p = 0.0266), MCV (r = 0.5126, p = 0.0007), and MPV (r = -0.4057, p = 0.0017). A correlation between disease duration and CRP was also observed (r = 0.4737, p = 0.0072). A correlation between disease duration and PLR was also observed (r = 0.4569, p = 0.0054).
Discussion
SLE is a rare autoimmune disease, the mortality of which is significantly associated with cardiovascular complications.
Finding markers that can be used in daily clinical practice, which are also easy to use and access, is important in the progression of the disease. This study showed a negative correlation between the distance traveled in 6MWT by patients with SLE and the duration of the disease. During clinical progression, a smaller distance traveled was observed in the SLE group; a similar relationship was observed in relation to the control group.
In their study, Huang, Yao and Huang "Role of echocardiography for early detection of cardiac lesions in asymptomatic SLE," described echocardiography as a noninvasive diagnostic test enabling the early detection of cardiovascular complications, thus resulting in earlier treatment and in reductions in mortality and morbidity. They analyzed 40 patients with SLE, and left ventricular systolic dysfunction was diagnosed in 25% of these patients. The study showed that, in many cases of a serologically active disease, there were no clinical symptoms and changes were only detected on TTE [22] . Echocardiography has an important role in the detection and control of cardiovascular disease. In addition to LVEF assessment, it is possible to demonstrate regional and general systolic dysfunction, and LVEDD measurements also provide important information on the enlargement of the left ventricle muscle. [14] . Leite presented a 6MWT study in 42 patients with SLE. The average distance traveled by the patients was 478 ± 82 m. A significant correlation was found between decreased saturation and the distance traveled by the patients in 6MWT [24] . In both studies, a significantly smaller distance in 6MWT was covered by patients with SLE. Similar results were obtained in the study group. There were no important differences between the SLE and control groups in blood pressure and heart rate. Significantly higher values of parameters were obtained in a subjective study of fatigue and dyspnea according to the Borg scale.
Hematologic abnormalities are a common complication of SLE. Anemia is present in almost half of the patients. It is mostly associated with chronic inflammation and changes in iron levels, as well as with reduced erythropoietin activity [25] [26] [27] [28] . In the group of patients with SLE, the hemoglobin concentration was lower than that in the control group.
Almost 20% of patients with SLE were found to have anemia. SLE assessment should be comprehensive and should include laboratory tests, such as measurements of MPV and CRP, which are indicators of inflammation and significantly correlate with the disease duration and results of imaging tests (e.g., TTE), which are used to assess cardiac dysfunction. In later phases, magnetic resonance imaging should be considered to more accurately observe the structure of the heart [11] . In the present study, the significantly higher [29] . The lower MPV values obtained in the study group were probably associated with higher disease activity. The CRP level was elevated, which indicates the progression of the disease. 
Conclusions
Echocardiographic examination may significantly influence the further treatment and prevention of cardiovascular complications and the reduction of mortality in patients with SLE. This test especially should be carried out among
